BindingDB

The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.4K Targets. Of those, 1.6M data for 748K Compounds and 4.8K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Donate Now

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

Advanced Search

25 articles for thisTarget

The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Pyrimidinopyrimidine inhibitors of ketohexokinase: exploring the ring C2 group that interacts with Asp-27B in the ligand binding pocket.EBI
Janssen Pharmaceutical Companies of Johnson & Johnson
Inhibitors of Ketohexokinase: Discovery of Pyrimidinopyrimidines with Specific Substitution that Complements the ATP-Binding Site.EBI
TBA
Optimization of a pyrazole hit from FBDD into a novel series of indazoles as ketohexokinase inhibitors.EBI
Johnson & Johnson Pharmaceutical Research and Development
Novel Cyanopyridine Compounds as KHK Inhibitors for Treating NAFLD, NASH, and Type II Diabetes.EBI
Smith, Gambrell & Russell
Identification of LY3522348: A Highly Selective and Orally Efficacious Ketohexokinase Inhibitor.EBI
Eli Lilly
Discovery of a Novel Ketohexokinase Inhibitor with Improved Drug Distribution in Target Tissue for the Treatment of Fructose Metabolic Disease.EBI
Tuojie Biotech (Shanghai) Co.
Oxetanes in Drug Discovery Campaigns.EBI
Imperial College London
Small-Molecule Kinase Inhibitors for the Treatment of Nononcologic Diseases.EBI
Hefei University of Technology
Discovery of PF-06835919: A Potent Inhibitor of Ketohexokinase (KHK) for the Treatment of Metabolic Disorders Driven by the Overconsumption of Fructose.EBI
Pfizer
The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease.EBI
Terns Pharmaceuticals
Discovery of Fragment-Derived Small Molecules for in Vivo Inhibition of Ketohexokinase (KHK).EBI
Pfizer
Pyrimidine Derivatives As Modulators of the 5-HT2A Serotonin Receptor Useful For The Treatment of Disorders Related TheretoBDB
Arena Pharmaceuticals
Cyclin-dependent kinase degraders and methods of useBDB
Dana-Farber Cancer Institute
SUBSTITUTED TRIAZOLE DERIVATIVE, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOFBDB
Shanghai Simr Biotechnology
Methods of Treating LymphedemaBDB
Celltaxis
HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USEBDB
Amgen
Uracil compound as c-MET/AXL inhibitorBDB
Medshine Discovery
Apoptosis signal-regulating kinase inhibitorsBDB
Gilead Sciences
5-membered and bicyclic heterocyclic amides as inhibitors of rockBDB
Bristol-Myers Squibb
Imidazopyrrolopyridine as inhibitors of the JAK family of kinasesBDB
Janssen Pharmaceutica
Heteroaryl compounds useful as inhibitors of SUMO activating enzymeBDB
Millennium Pharmaceuticals
Cyclin dependent kinase inhibitorsBDB
Pfizer
Selective inhibitors of human corticosteroid synthasesBDB
Universitat Des Saarlandes
Spirocyclic molecules as protein kinase inhibitorsBDB
Nanjing Allgen Pharma